Primary sclerosing cholangitis and the microbiota: Current knowledge and perspectives on etiopathogenesis and emerging therapies

James H. Tabibian, Steven P. O'Hara, Keith D. Lindor

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC) is a chronic, fibroinflammatory, cholestatic liver disease of unknown etiopathogenesis. PSC generally progresses to liver cirrhosis, is a major risk factor for hepatobiliary and colonic neoplasia, and confers a median survival to death or liver transplantation of only 12 years. Although it is well recognized that approximately 75% of patients with PSC also have inflammatory bowel disease (IBD), the significance of this association remains elusive. Accumulating evidence now suggests a potentially important role for the intestinal microbiota, and enterohepatic circulation of molecules derived therefrom, as a putative mechanistic link between PSC and IBD and a central pathobiological driver of PSC. In this concise review, we provide a summary of and perspectives regarding the relevant basic, translational, and clinical data, which, taken together, encourage further investigation of the role of the microbiota and microbial metabolites in the etiopathogenesis of PSC and as a potential target for novel pharmacotherapies.

Original languageEnglish (US)
Pages (from-to)901-908
Number of pages8
JournalScandinavian Journal of Gastroenterology
Volume49
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Sclerosing Cholangitis
Microbiota
Inflammatory Bowel Diseases
Therapeutics
Enterohepatic Circulation
Liver Cirrhosis
Liver Transplantation
Liver Diseases
Drug Therapy
Survival
Neoplasms

Keywords

  • Cholestatic
  • Etiopathogenesis
  • Metabolites

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Primary sclerosing cholangitis and the microbiota : Current knowledge and perspectives on etiopathogenesis and emerging therapies. / Tabibian, James H.; O'Hara, Steven P.; Lindor, Keith D.

In: Scandinavian Journal of Gastroenterology, Vol. 49, No. 8, 2014, p. 901-908.

Research output: Contribution to journalArticle

@article{3a5fdd49c9c0424ea3bb295d65082acc,
title = "Primary sclerosing cholangitis and the microbiota: Current knowledge and perspectives on etiopathogenesis and emerging therapies",
abstract = "Primary sclerosing cholangitis (PSC) is a chronic, fibroinflammatory, cholestatic liver disease of unknown etiopathogenesis. PSC generally progresses to liver cirrhosis, is a major risk factor for hepatobiliary and colonic neoplasia, and confers a median survival to death or liver transplantation of only 12 years. Although it is well recognized that approximately 75{\%} of patients with PSC also have inflammatory bowel disease (IBD), the significance of this association remains elusive. Accumulating evidence now suggests a potentially important role for the intestinal microbiota, and enterohepatic circulation of molecules derived therefrom, as a putative mechanistic link between PSC and IBD and a central pathobiological driver of PSC. In this concise review, we provide a summary of and perspectives regarding the relevant basic, translational, and clinical data, which, taken together, encourage further investigation of the role of the microbiota and microbial metabolites in the etiopathogenesis of PSC and as a potential target for novel pharmacotherapies.",
keywords = "Cholestatic, Etiopathogenesis, Metabolites",
author = "Tabibian, {James H.} and O'Hara, {Steven P.} and Lindor, {Keith D.}",
year = "2014",
doi = "10.3109/00365521.2014.913189",
language = "English (US)",
volume = "49",
pages = "901--908",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Primary sclerosing cholangitis and the microbiota

T2 - Current knowledge and perspectives on etiopathogenesis and emerging therapies

AU - Tabibian, James H.

AU - O'Hara, Steven P.

AU - Lindor, Keith D.

PY - 2014

Y1 - 2014

N2 - Primary sclerosing cholangitis (PSC) is a chronic, fibroinflammatory, cholestatic liver disease of unknown etiopathogenesis. PSC generally progresses to liver cirrhosis, is a major risk factor for hepatobiliary and colonic neoplasia, and confers a median survival to death or liver transplantation of only 12 years. Although it is well recognized that approximately 75% of patients with PSC also have inflammatory bowel disease (IBD), the significance of this association remains elusive. Accumulating evidence now suggests a potentially important role for the intestinal microbiota, and enterohepatic circulation of molecules derived therefrom, as a putative mechanistic link between PSC and IBD and a central pathobiological driver of PSC. In this concise review, we provide a summary of and perspectives regarding the relevant basic, translational, and clinical data, which, taken together, encourage further investigation of the role of the microbiota and microbial metabolites in the etiopathogenesis of PSC and as a potential target for novel pharmacotherapies.

AB - Primary sclerosing cholangitis (PSC) is a chronic, fibroinflammatory, cholestatic liver disease of unknown etiopathogenesis. PSC generally progresses to liver cirrhosis, is a major risk factor for hepatobiliary and colonic neoplasia, and confers a median survival to death or liver transplantation of only 12 years. Although it is well recognized that approximately 75% of patients with PSC also have inflammatory bowel disease (IBD), the significance of this association remains elusive. Accumulating evidence now suggests a potentially important role for the intestinal microbiota, and enterohepatic circulation of molecules derived therefrom, as a putative mechanistic link between PSC and IBD and a central pathobiological driver of PSC. In this concise review, we provide a summary of and perspectives regarding the relevant basic, translational, and clinical data, which, taken together, encourage further investigation of the role of the microbiota and microbial metabolites in the etiopathogenesis of PSC and as a potential target for novel pharmacotherapies.

KW - Cholestatic

KW - Etiopathogenesis

KW - Metabolites

UR - http://www.scopus.com/inward/record.url?scp=84904414417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904414417&partnerID=8YFLogxK

U2 - 10.3109/00365521.2014.913189

DO - 10.3109/00365521.2014.913189

M3 - Article

C2 - 24990660

AN - SCOPUS:84904414417

VL - 49

SP - 901

EP - 908

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 8

ER -